載入...
TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
BACKGROUND: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine. DISCUSSION: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment o...
Na minha lista:
| 發表在: | BMC Cancer |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4932685/ https://ncbi.nlm.nih.gov/pubmed/27377645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2409-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|